Esomeprazole for treatment of GERD in pediatric patients
Study identifier:D9614C00097
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive.
Medical condition
Gastroesophageal reflux disease (GERD)
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole (Nexium)
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
1 Years - 11 Years
Date
Study Start Date: 01 Oct 2004
Primary Completion Date: -
Study Completion Date: 01 Oct 2005
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
